Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review

被引:0
|
作者
Moss, Kasey [1 ]
Gitman, Victor [2 ]
Sanchez, M. Ines Pinto [3 ,4 ]
Oczkowski, Simon [1 ,5 ]
Armstrong, David [4 ,6 ]
Jayakumar, Saumya [7 ,8 ]
Karvellas, Constantine Jason [8 ]
Selzner, Nazia [9 ]
Dionne, Joanna [10 ,11 ]
机构
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[3] McMaster Univ, Div Gastroenterol, Dept Med, Hamilton, ON, Canada
[4] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Hamilton, ON, Canada
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] McMaster Univ, Div Gastroenterol, Dept Med, Hamilton, ON, Canada
[7] Univ British Columbia, Div Gastroenterol, Dept Med, Vancouver, BC, Canada
[8] Univ Alberta, Div Gastroenterol, Dept Med, Edmonton, AB, Canada
[9] Univ Toronto, Div Gastroenterol, Dept Med, Toronto, ON, Canada
[10] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Dept Med, Hamilton, ON, Canada
[11] McMaster Univ, Farncombe Family Digest Hlth Res Inst, Dept Med, Hamilton, ON, Canada
来源
BMJ OPEN | 2024年 / 14卷 / 04期
关键词
Gastroenterology; NUTRITION & DIETETICS; Hepatology; Obesity; HEPATIC STEATOSIS; INDIVIDUALS; PREVALENCE; RISK;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Metabolic dysfunction-associated fatty liver disease (MASLD) is the hepatic manifestation of metabolic syndrome and the leading cause of chronic liver disease worldwide. Given that there is no pharmacological treatment for MASLD, it is imperative to understand whether lifestyle modifications may improve biochemical and pathological outcomes. One commonly proposed dietary modification is the Mediterranean diet; however, vegetarianism may also be a promising intervention. Vegetarianism has been shown to be associated with reduced morbidity and mortality in metabolic syndrome outcomes in coronary artery disease and diabetes; however, the relationship between vegetarian diet and MASLD is less clear. In this scoping review, we will provide a comprehensive overview of the current body of evidence related to a vegetarian diet and MASLD. Methods and analysis The aim of this scoping review is to describe and summarise the current body of evidence related to MASLD and a vegetarian diet. This review will be conducted using Arksey and O'Malley's framework. The literature review will be conducted using the following databases: SCOPUS, Web of Science, CINAHL-Plus, Cochrane Library and Medline. No restriction will be made on publication date. Included studies will encompass clinical trials and observational designs that examine effects or association of vegetarian diet in adults (>= 16 years) and report on the incidence, prevalence or progression of MASLD. Grey literature, non-human studies and articles focusing on changes in a specific food or nutraceutical will be excluded. Articles must have an English-language abstract available to be considered for inclusion. Screening and data extraction will be conducted by two independent reviewers. The findings will be summarised with descriptive statistics. Ethics and dissemination Approval from a medical ethics committee is not required for this review. Once the review is complete, the findings will be submitted to a peer-reviewed journal.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [32] Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Beyoglu, Diren
    Popov, Yury V.
    Idle, Jeffrey R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [33] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [34] Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Wong, Robert J.
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (04):
  • [35] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [36] Pharmacological management of pediatric metabolic dysfunction-associated steatotic liver disease
    Abou Jaoudeh, Rasha Abi Radi
    Hartmann, Phillipp
    Olson, Ole
    Gupta, Olga
    Kumar, Seema
    Ibrahim, Samar H.
    Fawaz, Rima
    Aqul, Amal
    Hassan, Sara
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2025, 80 (01) : 14 - 24
  • [37] Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease
    Pei, Yiying
    Goh, George Boon-Bee
    GUT AND LIVER, 2025, 19 (01) : 8 - 18
  • [38] Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rubino, Jessica M.
    Ring, Natalie Yanzi
    Patel, Krishna
    Xia, Xiaoqing
    Mackenzie, Todd A.
    diFlorio-Alexander, Roberta M.
    BIOMEDICINES, 2025, 13 (01)
  • [39] A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction-associated steatotic liver disease
    Grinshpan, Laura S.
    Haim, Yaara Even
    Ivancovsky-Wajcman, Dana
    Fliss-Isakov, Naomi
    Nov, Yuval
    Webb, Muriel
    Shibolet, Oren
    Kariv, Revital
    Zelber-Sagi, Shira
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [40] Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage
    Clayton-Chubb, Daniel
    Kemp, William W.
    Majeed, Ammar
    Lubel, John S.
    Woods, Robyn L.
    Tran, Cammie
    Ryan, Joanne
    Hodge, Alexander
    Schneider, Hans G.
    Mcneil, John J.
    Roberts, Stuart K.
    LIVER INTERNATIONAL, 2024, 44 (01) : 39 - 51